James Peyer: Why primary indications matter

“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs ever get regulatory approval? It’s simple: just choose a “primary indication” to test your drug with. Of course, that choice itself is rather difficult when you’re considering a geroprotector. Here’s how investors think about it…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD